Gluc3 glucose hexokinase kit

Study participants were identified as diabetes or non-diabetes based on blood biomarkers (C-peptide, HbA1c, glucose), self-reported diabetes and self-reported administration of anti-diabetes medications. Serum C-peptide levels were determined by the sandwich electrochemiluminescence immunoassay using Elecsys C-Peptide kit (Roche, Basel, Switzerland), while HbA1c in blood was measured using turbidimetric inhibition immunoassay (TINIA) utilizing Tina-quant HbA1c Gen. 3 kit (Roche) on hemolyzed blood samples and random glucose levels in serum were measured using the enzymatic reference method with GLUC3 glucose hexokinase kit (Roche), utilizing a COBAS instrument (Roche).
We classified our study cohort based on the phenotypic data provided by QBB. We first identified T1DM as self-declared diabetes subjects receiving insulin treatment exclusively and with serum C-peptide levels < 0.5 ng/mL. Subjects who did not meet the criteria for T1DM were classified as T2DM if they met any of the following criteria: self-declared diabetes, self-reported diabetes medication or with HbA1c > 6.5%. Subjects who did not meet the T1DM or T2DM criteria were classified as non-diabetes subjects.

The fasting blood sugar (FBS) was measured in freshly collected samples by Cobas c 501 (Roche, USA) using Gluc3-Glucose hexokinase kit (Catalogue no: 04404483–190) from Roche, USA.
The fasting serum insulin level was measured freshly collected samples by fully automated electro immunoassay analyzer (Cobas e 601 from Roche, USA) using Elecsys Insulin kit (Catalogue no: 12017547–122, from Roche, USA).
The level of HbA1c was estimated in freshly collected samples by Bio-Rad D-10 haemoglobin system (Bio-Rad, USA) using D-10 Hemoglobin A1c kit (Catalogue no: 220–0101, from Bio-Rad, USA).
Homeostatic model assessment-insulin resistance (HOMA-IR) was calculated using FBS and fasting insulin level.